Floatz logo

TEGAFUR

Rectal Cancer

Tokyo UniversitySmall moleculePhase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
73/ 100

Competitive context

114 Active assets in the Rectal Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
Fudan University
Phase 2BBB
Capecitabine
Gustave Roussy, Cancer Campus, Grand Paris
Phase 4BBB
Eloxatin
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3BBB
FLUOROURACILUM
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3BBB
Floxuridine
City of Hope Medical Center
Phase 2BBB

View all 50 →

Same molecule, other indications

TEGAFUR is also rated in:

cervical intraepithelial neoplasia grade 2/3Dormant
B
Indicative ·
59 / 100
View asset →
rectal cancerDormant
B
Indicative ·
59 / 100
View asset →
Adjuvant ChemotherapyDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →